Schizophrenia long-acting antipsychotics initiation index (SLAAII)

Introduction Background In individuals with schizophrenia, long-acting injectable antipsychotics (LAIs) have been shown to be beneficial in preventing relapse. An important issue in these individuals is poor medication adherence, which can negatively affect outcomes. Although currently underutiliz...

Full description

Bibliographic Details
Main Authors: P. Ifteni, A. Teodorescu
Format: Article
Language:English
Published: Cambridge University Press 2021-04-01
Series:European Psychiatry
Subjects:
Online Access:https://www.cambridge.org/core/product/identifier/S0924933821021490/type/journal_article
_version_ 1797616444091924480
author P. Ifteni
A. Teodorescu
author_facet P. Ifteni
A. Teodorescu
author_sort P. Ifteni
collection DOAJ
description Introduction Background In individuals with schizophrenia, long-acting injectable antipsychotics (LAIs) have been shown to be beneficial in preventing relapse. An important issue in these individuals is poor medication adherence, which can negatively affect outcomes. Although currently underutilized in comparison with oral antipsychotics, LAIs can be an important treatment option for addressing the high rates of poor adherence to medication in individuals with schizophrenia. There is a lack of published evidence and treatment guidelines on optimal strategies for the initiation of treatment with LAIs, which would at least partly explain why LAIs remain underutilized. Objectives Aims The aim of this report is to present an index for initiation of LAI in schizophrenia. Methods A restrospective chart review of a cohort of 1000 consecutive patients hospitalized with schizophrenia in Clinical Hospital of Psychiatry and Neurology Brasov, Romania, between 2011 and 2019. The number and reasons of LAIs initiation were evaluated. Results Rezults The results shows a reduced number of LAIs initiation and led to the realization of an index entitled Schizophrenia long-acting antipsychotics initiation index (SLAAII) with 6 domains (age, duration of illness, number of relapses, response to oral treatment and antipsychotic available formulation), each with 3 response variants rated with 5 points, 3 points and 1 point. The maximum posible score is 30 points and minimum 6 points. A score above 20 points is a strong indication for LAI initiation. Conclusions Schizophrenia long-acting antipsychotics initiation index (SLAAII) could be a very useful tool to facilitate the initiation of LAI treatment in patients with schizophrenia. Disclosure No significant relationships.
first_indexed 2024-03-11T07:41:16Z
format Article
id doaj.art-818990b17e864095a7c4dde19f105928
institution Directory Open Access Journal
issn 0924-9338
1778-3585
language English
last_indexed 2024-03-11T07:41:16Z
publishDate 2021-04-01
publisher Cambridge University Press
record_format Article
series European Psychiatry
spelling doaj.art-818990b17e864095a7c4dde19f1059282023-11-17T05:08:31ZengCambridge University PressEuropean Psychiatry0924-93381778-35852021-04-0164S813S81310.1192/j.eurpsy.2021.2149Schizophrenia long-acting antipsychotics initiation index (SLAAII)P. Ifteni0A. Teodorescu1Faculty Of Medicine, Transilvania University of Brasov, Brasov, RomaniaFaculty Of Medicine, Transilvania University of Brasov, Brasov, Romania Introduction Background In individuals with schizophrenia, long-acting injectable antipsychotics (LAIs) have been shown to be beneficial in preventing relapse. An important issue in these individuals is poor medication adherence, which can negatively affect outcomes. Although currently underutilized in comparison with oral antipsychotics, LAIs can be an important treatment option for addressing the high rates of poor adherence to medication in individuals with schizophrenia. There is a lack of published evidence and treatment guidelines on optimal strategies for the initiation of treatment with LAIs, which would at least partly explain why LAIs remain underutilized. Objectives Aims The aim of this report is to present an index for initiation of LAI in schizophrenia. Methods A restrospective chart review of a cohort of 1000 consecutive patients hospitalized with schizophrenia in Clinical Hospital of Psychiatry and Neurology Brasov, Romania, between 2011 and 2019. The number and reasons of LAIs initiation were evaluated. Results Rezults The results shows a reduced number of LAIs initiation and led to the realization of an index entitled Schizophrenia long-acting antipsychotics initiation index (SLAAII) with 6 domains (age, duration of illness, number of relapses, response to oral treatment and antipsychotic available formulation), each with 3 response variants rated with 5 points, 3 points and 1 point. The maximum posible score is 30 points and minimum 6 points. A score above 20 points is a strong indication for LAI initiation. Conclusions Schizophrenia long-acting antipsychotics initiation index (SLAAII) could be a very useful tool to facilitate the initiation of LAI treatment in patients with schizophrenia. Disclosure No significant relationships. https://www.cambridge.org/core/product/identifier/S0924933821021490/type/journal_articleschizophrenialong-acting antipsychoticsinitiation
spellingShingle P. Ifteni
A. Teodorescu
Schizophrenia long-acting antipsychotics initiation index (SLAAII)
European Psychiatry
schizophrenia
long-acting antipsychotics
initiation
title Schizophrenia long-acting antipsychotics initiation index (SLAAII)
title_full Schizophrenia long-acting antipsychotics initiation index (SLAAII)
title_fullStr Schizophrenia long-acting antipsychotics initiation index (SLAAII)
title_full_unstemmed Schizophrenia long-acting antipsychotics initiation index (SLAAII)
title_short Schizophrenia long-acting antipsychotics initiation index (SLAAII)
title_sort schizophrenia long acting antipsychotics initiation index slaaii
topic schizophrenia
long-acting antipsychotics
initiation
url https://www.cambridge.org/core/product/identifier/S0924933821021490/type/journal_article
work_keys_str_mv AT pifteni schizophrenialongactingantipsychoticsinitiationindexslaaii
AT ateodorescu schizophrenialongactingantipsychoticsinitiationindexslaaii